Skip to main content
John Davis II, MD, Oncology, Lee's Summit, MO

John M. Davis II MD

Breast Cancer, Hematologic Oncology, Melanoma


Assistant Professor University of Kansas Medical School

Join to View Full Profile
  • 4881 Ne Goodview CirLee's Summit, MO 64064

  • Phone+1 816-478-2050

  • Fax+1 816-503-4094

Dr. Davis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1991 - 1994
  • University of Missouri-Kansas City School of Medicine
    University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 1975 - 1978
  • University of Missouri Kansas City School of Medicine
    University of Missouri Kansas City School of MedicineClass of 1975

Certifications & Licensure

  • KS State Medical License
    KS State Medical License 1994 - 2025
  • MO State Medical License
    MO State Medical License 1976 - 2017

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Press Mentions

  • Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
    Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow TransplantFebruary 21st, 2019
  • Robotic Surgery for Cancer Treatment: What Patients Should Know
    Robotic Surgery for Cancer Treatment: What Patients Should KnowAugust 21st, 2018
  • Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders
    Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic DisordersApril 5th, 2018

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: